Every Form 4 that Tecogen Inc. (TGEN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TGEN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TGEN filings page.
TECOGEN INC. (symbol: TGEN) is the issuer of record for a Form 4/A filing submitted to the SEC. Lafaille Stephen reported acquisition or exercise transactions in this Form 4 filing.
TECOGEN INC. (TGEN) reported that its VP of Business Development, Stephen Lafaille, received a grant of 29,013 shares of Common Stock as a restricted stock award on June 26, 2026 under the Tecogen Inc. 2022 Stock Incentive Plan. The award vests with restrictions lapsing 25% per year, and this amendment corrects his beneficially owned shares to 41,389 following the grant. No Rule 10b5-1 trading plan is reported.
TECOGEN INC. (symbol: TGEN) is the issuer of record for a Form 4/A filing submitted to the SEC. Whiting John Kimball IV reported acquisition or exercise transactions in this Form 4 filing.
TECOGEN INC. (TGEN) reported an amended insider transaction for its General Counsel & Secretary, John Kimball Whiting IV. On June 26, 2026, he received a grant of 19,342 shares of restricted common stock at no cost under the Tecogen Inc. 2022 Stock Incentive Plan, with restrictions lapsing 25% per year. Following this award, his directly held common stock position is reported as 41,954 shares, correcting the previously reported post‑grant balance.
TECOGEN INC. (symbol: TGEN) is the issuer of record for a Form 4/A filing submitted to the SEC. Panora Robert reported acquisition or exercise transactions in this Form 4 filing.
TECOGEN INC. (TGEN) reports that COO and President Robert Panora received a grant of 9,671 shares of common stock on June 26, 2026 as a restricted stock award under the Tecogen Inc. 2022 Stock Incentive Plan, with restrictions lapsing 25% per year. Following this award, his directly held beneficial ownership is 72,194 shares, correcting the previously reported post‑grant amount. No Rule 10b5‑1 trading plan is reported for this transaction.
TECOGEN INC. (symbol: TGEN) is the issuer of record for a Form 4/A filing submitted to the SEC. Deschenes Roger P. reported acquisition or exercise transactions in this Form 4 filing.
TECOGEN INC. (TGEN) reported that Chief Financial Officer Roger P. Deschenes received a grant of 29,013 shares of Common Stock on June 26, 2026 as a Restricted Stock Award under the Tecogen Inc. 2022 Stock Incentive Plan, with restrictions lapsing 25% per year. Following this equity award, Deschenes is reported to beneficially own 81,975 shares of Tecogen common stock. The amendment corrects the number of shares beneficially owned that was previously reported on June 30, 2026, and no Rule 10b5-1 trading plan is reported for this award.
TECOGEN INC. (symbol: TGEN) is the issuer of record for a Form 4/A filing submitted to the SEC. Rangesh Abinand reported acquisition or exercise transactions in this Form 4 filing.
TECOGEN INC. (TGEN) reported that its Chief Executive Officer and director, Rangesh Abinand, received a grant of 174,081 shares of Common Stock as a restricted stock award on June 26, 2026 under the Tecogen Inc. 2022 Stock Incentive Plan, with restrictions lapsing 25% per year. This amended filing corrects the number of shares beneficially owned after the grant to 241,274 shares, and no Rule 10b5-1 trading plan is reported.
Whiting John Kimball IV reported acquisition or exercise transactions in this Form 4 filing.
TECOGEN INC. reported that its General Counsel & Secretary, John Kimball Whiting IV, received a grant of 19,342 shares of Common Stock as a restricted stock award under the 2022 Stock Incentive Plan. The award vests in four equal installments of 25% per year. Following this grant, he directly holds 19,342 shares.
Lafaille Stephen reported acquisition or exercise transactions in this Form 4 filing.
TECOGEN INC. reported that VP of Business Development Stephen Lafaille received a grant of 29,013 shares of common stock as a compensation award. The shares were granted at no cash cost to him and are structured as a Restricted Stock Award under the company’s 2022 Stock Incentive Plan.
The award vests in stages, with 25% of the shares vesting each year, which is designed to encourage long-term alignment with the company’s performance and retention over several years. Following this grant, Lafaille holds 29,013 common shares directly, with no derivative securities reported in this filing.
TECOGEN INC. Chief Accounting Officer Roger P. Deschenes reported an acquisition of 29,013 shares of common stock through a restricted stock award. The award was granted at no cash cost per share and represents his entire directly held position after the transaction. The grant vests in equal 25% installments each year under the company’s 2022 Stock Incentive Plan, meaning the shares become fully owned over four years as service conditions are met.
Tecogen Inc. reported that COO and President Robert Panora received new equity awards. He acquired 9,671 shares of Common Stock as a restricted stock award under the 2022 Stock Incentive Plan, with the grant made at no cash cost to him.
Panora was also granted stock options covering 26,041 shares of Common Stock at an exercise price of $5.17 per share. The options are incentive stock options under the 2022 Stock Incentive Plan, vesting 25% per year and expiring on June 26, 2036. After these grants, his reported direct holdings from this award are 9,671 shares and 26,041 options.
Tecogen Inc. director and CEO Rangesh Abinand received new equity awards in the form of common stock and stock options. He was granted 174,081 shares of common stock as a restricted stock award at no cash cost, vesting 25% per year under the 2022 Stock Incentive Plan. He also received an incentive stock option covering 26,041 shares of common stock at an exercise price of $5.17 per share, which also vests 25% per year and is exercisable until June 26, 2036. Following these grants, his reported direct holdings are 174,081 common shares and options on 26,041 shares.
TECOGEN INC. director Susan B. Hirsch received a compensation-related stock option grant covering 25,000 shares of common stock. The option has an exercise price of $5.17 per share and vests in equal 25% installments per year, providing potential future ownership if exercised. Following this award, Hirsch holds stock options for 25,000 shares directly.
Tecogen Inc. director John M. Albertine received a grant of stock options covering 25,000 shares of common stock. The options have an exercise price of $5.17 per share, vest 25% per year, and are scheduled to expire on June 26, 2036. Following this grant, he holds 25,000 derivative securities directly.
Tecogen Inc. director Earl Lewis reported a stock option grant for 25,000 shares of common stock. The option has an exercise price of $5.17 per share and vests in equal 25% installments each year. It expires on June 26, 2036, and this grant brings his directly held derivative position to 25,000 options.
TECOGEN INC. director Ahmed Ghoniem received a grant of stock options giving the right to buy 25,000 shares of common stock. The options have an exercise price of $5.1700 per share and vest 25% per year. Following this grant, he holds 25,000 derivative securities directly, with these options exercisable beginning on June 26, 2027 and expiring on June 26, 2036.
Tecogen Inc. director Angelina Galiteva reported an equity compensation grant in the form of a stock option. She received options to buy 25,000 shares of common stock at an exercise price of $5.17 per share, vesting 25% per year.
The options become exercisable starting on June 26, 2027 and expire on June 26, 2036. After this grant, she holds stock options covering 25,000 underlying shares directly. This is a compensation-related award, not an open-market purchase or sale.
TECOGEN INC. director Ahmed Ghoniem reported new share ownership through an option exercise and related stock purchase. He completed an open-market purchase of 12,723 shares of common stock at $0.786 per share and exercised stock options for 12,723 shares at the same price. Following these transactions, he holds 12,723 common shares directly and no remaining options from this grant.
TECOGEN INC. director Susan B. Hirsch reported an open-market purchase of 5,000 shares of the company’s Common Stock. The shares were bought at a price of $3.73 per share. After this transaction, she directly owns 265,416 Common Stock shares.
TECOGEN INC. director Susan B. Hirsch reported an open-market purchase of 10,000 shares of common stock at $2.54 per share. Following this buy, she directly holds 260,416 common shares, increasing her personal stake in the company.
Tecogen Inc. director Earl Lewis reported an open-market purchase of 5,000 shares of Tecogen common stock at an average price of $2.5192 per share. The filing shows that, following this transaction, Lewis directly or through a trust associated with him holds 1,011,006 Tecogen shares.
TECOGEN INC. director Earl Lewis reported an open-market purchase of the company’s common stock through a trust. The trust acquired 5,000 shares at an average price of $2.8817 per share on March 26, 2026. Following this transaction, holdings associated with Lewis total 1,006,006 shares of common stock, indicating a relatively small incremental increase to an already substantial position.
Tecogen Inc. reported that its General Counsel and Secretary, John Kimball Whiting IV, made an open-market purchase of Common Stock. He bought 10,000 shares at $2.38 per share and now directly owns 22,612 shares. This filing highlights an increase in his personal stake in the company.
TECOGEN INC. Chief Accounting Officer Roger P. Deschenes bought additional company stock in the open market. On March 20, 2026, he purchased 10,000 shares of common stock at $2.23 per share. Following this transaction, he directly holds 52,962 shares of Tecogen common stock.
TECOGEN INC. Chief Executive Officer and Chief Financial Officer Rangesh Abinand reported an open-market purchase of 3,000 shares of common stock on 2026-03-20 at a price of $2.298 per share. Following this transaction, his directly reported holdings increased to 67,193 shares of common stock.
According to a footnote, 2,500 of the purchased shares were acquired by Rangesh Abinand and 500 shares were acquired by his daughter, all reported in this Form 4. The transaction is classified as a non-derivative, open-market purchase.
TECOGEN INC. director John Hatsopoulos exercised stock options to acquire 50,000 shares of Common Stock at $0.88 per share under a Stock Option Agreement dated September 20, 2023. Following the exercise, he directly owns 1,038,951 shares of Tecogen Common Stock, indicating an exercise-and-hold transaction with no same-day share sale disclosed.